An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Stanley Cohen, Jose L. Pablos, Karel Pavelka, Gerard Anton Müller, Alan Matsumoto, Alan Kivitz, Hui Wang, Eswar Krishnan

ABSTRACT

BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). METHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline. RESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade ≥ 3 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was - 2.25 at the OLE study baseline (n = 440), - 2.36 at week 4 (n = 463), - 2.41 at week 24 (n = 450), - 2.55 at week 48 (n = 433), and - 2.60 at week 70 (n = 412). Efficacy was maintained throughout the study. CONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity. TRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931. More... »

PAGES

84

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3

DOI

http://dx.doi.org/10.1186/s13075-019-1857-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113057001

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30922373


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Metroplex Clinical Research Center", 
          "id": "https://www.grid.ac/institutes/grid.477482.a", 
          "name": [
            "Internal Medicine, Rheumatology Division, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, 75231, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "Stanley", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario 12 De Octubre", 
          "id": "https://www.grid.ac/institutes/grid.144756.5", 
          "name": [
            "Instituto de Investigaci\u00f3n Hospital 12 de Octubre, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pablos", 
        "givenName": "Jose L.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Revmatologick\u00fd \u00fastav", 
          "id": "https://www.grid.ac/institutes/grid.418965.7", 
          "name": [
            "Institute of Rheumatology, Prague 2, Czech Republic"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pavelka", 
        "givenName": "Karel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Abteilung.f\u00fcr Nephrologie und Rheumatologie, G\u00f6ttingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "M\u00fcller", 
        "givenName": "Gerard Anton", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Arthritis and Rheumatism Associates", 
          "id": "https://www.grid.ac/institutes/grid.490547.b", 
          "name": [
            "Arthritis and Rheumatism Associates, Wheaton, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumoto", 
        "givenName": "Alan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Abteilung f\u00fcr Nephrologie und Rheumatologie, G\u00f6ttingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kivitz", 
        "givenName": "Alan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Biosimilars Development, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Hui", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Biosimilars Development, Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Krishnan", 
        "givenName": "Eswar", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/rheumatology/ket260", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000218995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.22214", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009901742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2016.01.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012251139"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/ker124", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012965699"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/1744666x.2015.1090313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013216059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017993092"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-209166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023109204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/ar3147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024364202", 
          "https://doi.org/10.1186/ar3147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2016.01.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032526040"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2015.04.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037699729"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0184-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038300105", 
          "https://doi.org/10.1007/s40259-016-0184-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0184-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038300105", 
          "https://doi.org/10.1007/s40259-016-0184-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11926-016-0601-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040002812", 
          "https://doi.org/10.1007/s11926-016-0601-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11926-016-0601-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040002812", 
          "https://doi.org/10.1007/s11926-016-0601-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0185-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042463549", 
          "https://doi.org/10.1007/s40259-016-0185-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-016-0185-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042463549", 
          "https://doi.org/10.1007/s40259-016-0185-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0049-0172(90)90060-s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045775208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078771680", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaad.2016.12.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084083514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-017-0218-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085050557", 
          "https://doi.org/10.1007/s40259-017-0218-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-017-0218-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085050557", 
          "https://doi.org/10.1007/s40259-017-0218-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2016-210459", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085872012"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.15857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090920617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.15857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090920617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1106025459", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA).\nMETHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40\u2009mg ABP 501 every other week for 68\u2009weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline.\nRESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade\u2009\u2265\u20093 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was -\u20092.25 at the OLE study baseline (n\u2009=\u2009440), -\u20092.36 at week 4 (n\u2009=\u2009463), -\u20092.41 at week 24 (n\u2009=\u2009450), -\u20092.55 at week 48 (n\u2009=\u2009433), and -\u20092.60 at week 70 (n\u2009=\u2009412). Efficacy was maintained throughout the study.\nCONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity.\nTRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13075-019-1857-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297499", 
        "issn": [
          "1478-6354", 
          "1478-6362"
        ], 
        "name": "Arthritis Research & Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "name": "An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis", 
    "pagination": "84", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13075-019-1857-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113057001"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9c2f7819fbddef15635892850b461d152ea07841efcdb7f2f174243af446fe38"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101154438"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30922373"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13075-019-1857-3", 
      "https://app.dimensions.ai/details/publication/pub.1113057001"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106834_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13075-019-1857-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13075-019-1857-3'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      21 PREDICATES      49 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13075-019-1857-3 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N9f2976c09eb8400b9b76213703808eed
4 schema:citation sg:pub.10.1007/s11926-016-0601-0
5 sg:pub.10.1007/s40259-016-0184-3
6 sg:pub.10.1007/s40259-016-0185-2
7 sg:pub.10.1007/s40259-017-0218-5
8 sg:pub.10.1186/ar3147
9 https://app.dimensions.ai/details/publication/pub.1078771680
10 https://app.dimensions.ai/details/publication/pub.1106025459
11 https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w
12 https://doi.org/10.1002/art.22214
13 https://doi.org/10.1016/0049-0172(90)90060-s
14 https://doi.org/10.1016/j.jaad.2016.12.014
15 https://doi.org/10.1016/j.semarthrit.2015.04.002
16 https://doi.org/10.1016/j.semarthrit.2016.01.001
17 https://doi.org/10.1016/j.semarthrit.2016.01.002
18 https://doi.org/10.1093/rheumatology/ker124
19 https://doi.org/10.1093/rheumatology/ket260
20 https://doi.org/10.1111/bjd.15857
21 https://doi.org/10.1136/annrheumdis-2016-209166
22 https://doi.org/10.1136/annrheumdis-2016-210459
23 https://doi.org/10.1586/1744666x.2015.1090313
24 schema:datePublished 2019-12
25 schema:datePublishedReg 2019-12-01
26 schema:description BACKGROUND: ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). METHODS: Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 weeks. Key safety endpoints included treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and anti-drug antibody (ADA) incidences. Efficacy endpoints included ACR20 (at least 20% improvement in American College of Rheumatology core set measurements from baseline) and Disease Activity Score 28-joint count C-reactive protein (DAS28-CRP) change from baseline. RESULTS: Among 466/467 patients treated with ABP 501, 229 transitioned from the ABP 501 arm of the parent study (ABP 501/ABP 501) and 237 from the adalimumab RP arm (RP/ABP 501); 412/467 (88.2%) patients completed the study. The overall TEAE incidence was 63.7% (297/466); grade ≥ 3 TEAE incidence was 9.0% (42/466). The incidence of TEAEs leading to discontinuation of investigational product was 3.6% (17/466). The SAE incidence was 9.9% (46/466). Overall, 18.2% (85/466) of subjects developed binding ADAs and 6.9% (32/466) developed neutralizing ADAs in the OLE study. The ACR20 response rate was 73.3% (340/464 subjects) at OLE baseline, and 78.8% (327/415 subjects) at week 70 of the OLE study. The overall mean DAS28-CRP change from the parent study baseline was - 2.25 at the OLE study baseline (n = 440), - 2.36 at week 4 (n = 463), - 2.41 at week 24 (n = 450), - 2.55 at week 48 (n = 433), and - 2.60 at week 70 (n = 412). Efficacy was maintained throughout the study. CONCLUSIONS: Efficacy previously demonstrated in the parent study was maintained in this OLE study with no new safety findings. Long-term safety, immunogenicity, and efficacy were similar in the ABP 501/ABP 501 and RP/ABP 501 groups. The single switch from RP to ABP 501 did not impact immunogenicity. TRIAL REGISTRATION: ClinicalTrial.gov, NCT02114931.
27 schema:genre research_article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf Naba3f2d5b6a242c4b914d370c9450f43
31 Nea650f6ae05f4b52a08f3cfd868375ab
32 sg:journal.1297499
33 schema:name An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
34 schema:pagination 84
35 schema:productId N6854a5c38b374e0b85036ffc247fb93f
36 N76f73a39b5b64f10afd66a746135e8cc
37 Na7b1d389abd147ecb1f73a6010c9e6ed
38 Ndeef61f3fe934b88a6b92ba27f832a1d
39 Nfb4a6e00c137476a99eaa256f632ef02
40 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113057001
41 https://doi.org/10.1186/s13075-019-1857-3
42 schema:sdDatePublished 2019-04-16T06:25
43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
44 schema:sdPublisher N92bee301576d447687c0f0cd2b062e59
45 schema:url https://link.springer.com/10.1186%2Fs13075-019-1857-3
46 sgo:license sg:explorer/license/
47 sgo:sdDataset articles
48 rdf:type schema:ScholarlyArticle
49 N03960735d72245fbbe91d91f731e82eb schema:affiliation Nfec844c910ec40979a25ff14e4cf18c6
50 schema:familyName Müller
51 schema:givenName Gerard Anton
52 rdf:type schema:Person
53 N1b15edabf96246d69e6423948ccad3e2 rdf:first N60a778f3c4b9446b81bf7ade2c96e34a
54 rdf:rest N4de68823923e40829af831c2459e8d21
55 N3bc96f6ea9754608afcb167c7ec62b53 schema:affiliation https://www.grid.ac/institutes/grid.477482.a
56 schema:familyName Cohen
57 schema:givenName Stanley
58 rdf:type schema:Person
59 N460b9564f4e74bf2b5507cd743d440f2 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
60 schema:familyName Krishnan
61 schema:givenName Eswar
62 rdf:type schema:Person
63 N47f00a17726340698799ec3b58b93c77 schema:affiliation https://www.grid.ac/institutes/grid.144756.5
64 schema:familyName Pablos
65 schema:givenName Jose L.
66 rdf:type schema:Person
67 N4de68823923e40829af831c2459e8d21 rdf:first N03960735d72245fbbe91d91f731e82eb
68 rdf:rest Nc2b81762aa9249d8a5ee36b405e91ce6
69 N60a778f3c4b9446b81bf7ade2c96e34a schema:affiliation https://www.grid.ac/institutes/grid.418965.7
70 schema:familyName Pavelka
71 schema:givenName Karel
72 rdf:type schema:Person
73 N6854a5c38b374e0b85036ffc247fb93f schema:name pubmed_id
74 schema:value 30922373
75 rdf:type schema:PropertyValue
76 N6feb5925007d41788741de5aff49597f schema:affiliation Nf964e95f1c074254ad9dabb0a276c502
77 schema:familyName Kivitz
78 schema:givenName Alan
79 rdf:type schema:Person
80 N73a75a6ec63746838ba38c0e414692e2 schema:affiliation https://www.grid.ac/institutes/grid.490547.b
81 schema:familyName Matsumoto
82 schema:givenName Alan
83 rdf:type schema:Person
84 N76f73a39b5b64f10afd66a746135e8cc schema:name nlm_unique_id
85 schema:value 101154438
86 rdf:type schema:PropertyValue
87 N7ac3ec8c4a424412b49fd76524cb83f2 rdf:first N460b9564f4e74bf2b5507cd743d440f2
88 rdf:rest rdf:nil
89 N7b88e3cfa1cb471fb35db3c8e81459f8 rdf:first N92c701e9f7bb4732900f03591318c628
90 rdf:rest N7ac3ec8c4a424412b49fd76524cb83f2
91 N92bee301576d447687c0f0cd2b062e59 schema:name Springer Nature - SN SciGraph project
92 rdf:type schema:Organization
93 N92c701e9f7bb4732900f03591318c628 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
94 schema:familyName Wang
95 schema:givenName Hui
96 rdf:type schema:Person
97 N9f2976c09eb8400b9b76213703808eed rdf:first N3bc96f6ea9754608afcb167c7ec62b53
98 rdf:rest Nc3390e06b2b94189885394331906746b
99 Na7b1d389abd147ecb1f73a6010c9e6ed schema:name readcube_id
100 schema:value 9c2f7819fbddef15635892850b461d152ea07841efcdb7f2f174243af446fe38
101 rdf:type schema:PropertyValue
102 Naba3f2d5b6a242c4b914d370c9450f43 schema:volumeNumber 21
103 rdf:type schema:PublicationVolume
104 Nc2b81762aa9249d8a5ee36b405e91ce6 rdf:first N73a75a6ec63746838ba38c0e414692e2
105 rdf:rest Nca53591e5c5941d7bafcdbbb49780340
106 Nc3390e06b2b94189885394331906746b rdf:first N47f00a17726340698799ec3b58b93c77
107 rdf:rest N1b15edabf96246d69e6423948ccad3e2
108 Nca53591e5c5941d7bafcdbbb49780340 rdf:first N6feb5925007d41788741de5aff49597f
109 rdf:rest N7b88e3cfa1cb471fb35db3c8e81459f8
110 Ndeef61f3fe934b88a6b92ba27f832a1d schema:name dimensions_id
111 schema:value pub.1113057001
112 rdf:type schema:PropertyValue
113 Nea650f6ae05f4b52a08f3cfd868375ab schema:issueNumber 1
114 rdf:type schema:PublicationIssue
115 Nf964e95f1c074254ad9dabb0a276c502 schema:name Abteilung für Nephrologie und Rheumatologie, Göttingen, Germany
116 rdf:type schema:Organization
117 Nfb4a6e00c137476a99eaa256f632ef02 schema:name doi
118 schema:value 10.1186/s13075-019-1857-3
119 rdf:type schema:PropertyValue
120 Nfec844c910ec40979a25ff14e4cf18c6 schema:name Abteilung.für Nephrologie und Rheumatologie, Göttingen, Germany
121 rdf:type schema:Organization
122 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
123 schema:name Medical and Health Sciences
124 rdf:type schema:DefinedTerm
125 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
126 schema:name Clinical Sciences
127 rdf:type schema:DefinedTerm
128 sg:journal.1297499 schema:issn 1478-6354
129 1478-6362
130 schema:name Arthritis Research & Therapy
131 rdf:type schema:Periodical
132 sg:pub.10.1007/s11926-016-0601-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040002812
133 https://doi.org/10.1007/s11926-016-0601-0
134 rdf:type schema:CreativeWork
135 sg:pub.10.1007/s40259-016-0184-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038300105
136 https://doi.org/10.1007/s40259-016-0184-3
137 rdf:type schema:CreativeWork
138 sg:pub.10.1007/s40259-016-0185-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042463549
139 https://doi.org/10.1007/s40259-016-0185-2
140 rdf:type schema:CreativeWork
141 sg:pub.10.1007/s40259-017-0218-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085050557
142 https://doi.org/10.1007/s40259-017-0218-5
143 rdf:type schema:CreativeWork
144 sg:pub.10.1186/ar3147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024364202
145 https://doi.org/10.1186/ar3147
146 rdf:type schema:CreativeWork
147 https://app.dimensions.ai/details/publication/pub.1078771680 schema:CreativeWork
148 https://app.dimensions.ai/details/publication/pub.1106025459 schema:CreativeWork
149 https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1017993092
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1002/art.22214 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009901742
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1016/0049-0172(90)90060-s schema:sameAs https://app.dimensions.ai/details/publication/pub.1045775208
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1016/j.jaad.2016.12.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084083514
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1016/j.semarthrit.2015.04.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037699729
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1016/j.semarthrit.2016.01.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032526040
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1016/j.semarthrit.2016.01.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012251139
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1093/rheumatology/ker124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012965699
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1093/rheumatology/ket260 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000218995
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1111/bjd.15857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090920617
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1136/annrheumdis-2016-209166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023109204
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1136/annrheumdis-2016-210459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085872012
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1586/1744666x.2015.1090313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013216059
174 rdf:type schema:CreativeWork
175 https://www.grid.ac/institutes/grid.144756.5 schema:alternateName Hospital Universitario 12 De Octubre
176 schema:name Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain
177 rdf:type schema:Organization
178 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
179 schema:name Biosimilars Development, Amgen Inc., Thousand Oaks, CA, USA
180 rdf:type schema:Organization
181 https://www.grid.ac/institutes/grid.418965.7 schema:alternateName Revmatologický ústav
182 schema:name Institute of Rheumatology, Prague 2, Czech Republic
183 rdf:type schema:Organization
184 https://www.grid.ac/institutes/grid.477482.a schema:alternateName Metroplex Clinical Research Center
185 schema:name Internal Medicine, Rheumatology Division, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, 75231, Dallas, TX, USA
186 rdf:type schema:Organization
187 https://www.grid.ac/institutes/grid.490547.b schema:alternateName Arthritis and Rheumatism Associates
188 schema:name Arthritis and Rheumatism Associates, Wheaton, MD, USA
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...